8-K: Nu Skin Q4, Full-Year 2025 Results; 2026 Growth Forecast

Nu Skin Enterprises reported fourth quarter and full-year 2025 financial results within guidance, with over 50% growth in adjusted earnings for 2025, and provided an initial outlook for 2026, anticipating a return to revenue growth by year-end.

Summary

• Fourth quarter 2025 revenue was $370.3 million, a 16.9% decrease year-over-year, or a 10.4% decrease excluding Mavely 2024 revenue.
• Fourth quarter 2025 diluted Earnings Per Share (EPS) was $0.29, compared to $(0.73) in the prior-year quarter, or $0.38 excluding restructuring and other charges.
• Full-year 2025 revenue was $1.49 billion, a 14.3% decrease from 2024, or a 10.7% decrease excluding Mavely 2024 revenue.
• Full-year 2025 diluted EPS was $3.18, compared to $(2.95) in 2024, or $1.27 excluding Mavely gain and other charges.
• Customer count decreased by 10% year-over-year to 748,796 in Q4 2025.
• Paid Affiliates decreased by 11% year-over-year to 129,311 in Q4 2025.
• Sales Leaders decreased by 19% year-over-year to 30,045 in Q4 2025.
• The company achieved fourth quarter results within its guidance range for both revenue and earnings per share.
• Nu Skin is building sales leader alignment for the global launch of Prysm iO, positioning for a return to year-over-year revenue growth by the end of 2026.
• More than 20,000 Prysm iO intelligent wellness devices are already with sales leaders, generating over 700,000 scans.
• Pre-market activities have commenced in India, with a full market opening anticipated in the second half of 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed report. While the company met its guidance and showed strong adjusted EPS growth due to cost optimization, the underlying business metrics (revenue, customers, sales leaders) continue to decline, and the 2026 outlook suggests continued top-line pressure before a hoped-for recovery late in the year.

Positives

• Achieved fourth quarter and full-year 2025 revenue and EPS results within guidance.
• Full-year 2025 adjusted EPS grew over 50% to $1.27, compared to $0.84 in 2024, driven by margin improvement and cost optimization.
• Gross Margin improved to 70.7% in Q4 2025 from 62.7% in Q4 2024 (or 71.4% excluding inventory write-off).
• Operating Margin improved significantly to 6.3% in Q4 2025 from (11.9)% in Q4 2024 (or 7.7% excluding restructuring and other charges).
• Interest expense decreased to $4.0 million in Q4 2025 from $5.9 million in Q4 2024.
• Income tax rate decreased to 20.3% in Q4 2025 from 37.5% in Q4 2024.
• Cash and cash equivalents increased to $238.6 million as of December 31, 2025, up from $186.9 million in 2024.
• Long-term debt was reduced to $204.2 million as of December 31, 2025, from $363.6 million in 2024.
• Repurchased $10.0 million of stock in Q4 2025, with $142.3 million remaining in the current authorization.
• Global launch of Prysm iO intelligent wellness devices is underway, with over 20,000 devices distributed to sales leaders and generating more than 700,000 scans.
• Pre-market activities for India expansion are progressing, with a full market opening anticipated in the second half of 2026.

Negatives

• Fourth quarter 2025 revenue declined 16.9% to $370.3 million.
• Full-year 2025 revenue declined 14.3% to $1.49 billion.
• Customer count decreased 10% year-over-year to 748,796 in Q4 2025.
• Paid Affiliates decreased 11% year-over-year to 129,311 in Q4 2025.
• Sales Leaders decreased 19% year-over-year to 30,045 in Q4 2025.
• Q1 2026 revenue guidance of $320 to $340 million represents a projected decline of 7% to 12% year-over-year.
• Full-year 2026 revenue guidance of $1.35 to $1.50 billion represents a projected decline of 9% to 1% year-over-year (at the high end).
• Significant revenue declines across most geographic segments in Q4 and full-year 2025, including Southeast Asia/Pacific (-22.7% Q4), Mainland China (-7.8% Q4), and South Korea (-14.9% Q4).
• Rhyz Other revenue declined 82.8% in Q4 2025 and 79.1% in full-year 2025.

Risks

• Any failure of current or planned initiatives or products (e.g., Prysm iO) to generate sustained interest, sponsoring, and selling activities among the sales force and customers.
• Modification, interpretation, or enforcement of direct selling laws and regulations, particularly in the U.S. and Mainland China, which could negatively impact the business model, revenue, sales force, or operations (e.g., loss of licenses, fines).
• Adverse economic conditions and events globally.
• Future tax-planning initiatives, prospective or retrospective increases in duties or tariffs, adverse results of tax audits, or unfavorable changes to tax laws.
• Competitive pressures in the markets.
• Epidemics or other crises, and related disruptions, negatively impacting the business.
• Adverse publicity related to the business, products, industry, or any legal actions or complaints.
• Political, legal, tax, and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets.
• Uncertainty regarding meeting restrictions and government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China.
• Foreign-currency fluctuations and their currency translation impact on the business.
• Uncertainties regarding the future financial performance of acquired businesses.
• Risks related to accurately predicting, delivering, or maintaining sufficient product quantities, and increased risk of inventory write-offs due to over-forecasting demand or changes in initiatives.
• Regulatory risks associated with products, potentially requiring claim modifications or inhibiting import/sale if products are deemed medical devices or cannot be registered timely.

Future Outlook

Nu Skin anticipates a return to year-over-year revenue growth by the end of 2026, driven by the global launch of Prysm iO intelligent wellness devices in the second half of the year and the full market opening in India, also in the second half of 2026. For Q1 2026, revenue is projected to be $320 to $340 million with EPS of $0.10 to $0.20. Full-year 2026 revenue is guided at $1.35 to $1.50 billion with EPS of $0.80 to $1.20.

Management Comments

• "We are pleased to achieve fourth quarter results within our guidance range for both revenue and earnings per share." Ryan Napierski, President and CEO.
• "This past year was a pivotal year as we furthered our transformation toward becoming the worlds leading intelligent beauty and wellness platform and laid the groundwork for our 2026 growth initiatives." Ryan Napierski, President and CEO.
• "Looking ahead, we continue to build sales leader alignment in the first half of the year around the global launch of Prysm iO, positioning us for a return to year-over-year revenue growth by years end." Ryan Napierski, President and CEO.
• "More than 20,000 [Prysm iO] devices are already in the hands of our sales leaders generating more than 700,000 scans." Ryan Napierski, President and CEO.
• "We are pleased with how we performed this year, growing earnings by more than 50% due to effective margin improvement and cost optimization amidst top-line pressures." James D. Thomas, Chief Financial Officer.

Industry Context

StockSavvy.ai notes that Nu Skin's focus on an 'intelligent beauty and wellness platform' with products like Prysm iO aligns with broader industry trends towards personalized health technology and subscription-based models. However, the continued decline in customer, affiliate, and sales leader numbers, alongside overall revenue contraction, indicates significant challenges in a competitive direct-selling market where customer acquisition and retention are paramount. The expansion into India represents a strategic move into a high-growth market, a common tactic for mature direct selling companies seeking new avenues for growth.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through strategic initiatives (Prysm iO, India expansion) and continued stock repurchases, but ongoing revenue declines and a challenging 2026 outlook present risks.
• Employees/Sales Force (Paid Affiliates, Sales Leaders): Decreases in Paid Affiliates and Sales Leaders indicate challenges in recruitment and retention, potentially impacting compensation and morale. New product launches like Prysm iO aim to re-engage and grow the sales force.
• Customers: Introduction of Prysm iO aims to enhance personalized product recommendations and drive customer lifetime value, but overall customer numbers are declining.
• Creditors: Reduced long-term debt and a healthy cash position improve the company's financial stability.

Next Steps

• Continue building sales leader alignment around the global launch of Prysm iO in the first half of 2026.
• Execute the consumer launch of Prysm iO intelligent wellness devices in the second half of 2026.
• Achieve full market opening in India, anticipated in the back half of 2026.
• Focus on driving growth in subscriptions through Prysm iO to increase customer lifetime value.

Key Dates

Recommendation

While Nu Skin met its guidance and demonstrated strong adjusted EPS growth through cost management, the persistent decline in core business metrics like revenue, customer count, and sales leaders is concerning. The 2026 outlook projects continued revenue contraction before a potential recovery late in the year, contingent on the success of new initiatives like Prysm iO and India expansion. Given the mixed signals – operational improvements versus ongoing top-line challenges – a 'hold' recommendation is appropriate, awaiting clearer signs of sustained revenue growth and successful execution of strategic pivots.

Keywords

Nu Skin, NUS, Financial Results, Earnings, Q4 2025, Full-Year 2025, 2026 Outlook, Prysm iO, Intelligent Beauty, Wellness Platform, Direct Selling, Affiliate Marketing, Revenue Growth, EPS Growth, India Market, Stock Repurchase, Dividend, SEC Filing, 8-K